Hot Features
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a... Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.725 | -11.572226656 | 6.265 | 6.3 | 5.31 | 3192420 | 5.60258982 | CS |
| 4 | -1.5 | -21.3068181818 | 7.04 | 7.2 | 5.31 | 3199257 | 6.17105869 | CS |
| 12 | -0.16 | -2.80701754386 | 5.7 | 7.43 | 5.105 | 3567883 | 6.17823855 | CS |
| 26 | -0.33 | -5.62180579216 | 5.87 | 8.4 | 5.105 | 4059133 | 6.49207122 | CS |
| 52 | 1.84 | 49.7297297297 | 3.7 | 8.4 | 3.49 | 3967210 | 5.81414277 | CS |
| 156 | 2.04 | 58.2857142857 | 3.5 | 10.13 | 3.16 | 4738049 | 5.6801926 | CS |
| 260 | -1.26 | -18.5294117647 | 6.8 | 10.13 | 0.4902 | 5843324 | 3.7938817 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.